- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of March 26
The Center for Biosimilars® recaps the top 5 biosimilars articles for the week of March 26, 2018.
Transcript:
Hi, I'm Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of March 26.
Number 5: A new brief from Avalere Health says that a variety of policy options are available to the United States to create the necessary conditions for biosimilar competition.
Number 4: Mylan and Biocon's Lantus biosimilar has received marketing authorization in the European Union and in Australia.
Number 3: Intravitreal anti-vascular endothelial growth factor treatments, including bevacizumab, are not associated with an increased risk of adverse events.
Number 2: In a symposium at the 23rd annual conference of the National Comprehensive Cancer Network, 3 clinicians presented on the use of biosimilars in oncology.
Number 1: FDA Commissioner, Dr Scott Gottlieb, said this week that the FDA is working on numerous new policies to encourage biosimilar development.
Finally, last week, our e-newsletter asked whether you think Oregon's new drug price transparency law will help to control costs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
